Check 35,000+ stocks against 26 valuation models and 37 quality factors

China Resources Pharmaceutical Group Ltd (3320) fair value: what the stock is really worth

As of Sep 28, 2026: fair value of China Resources Pharmaceutical Group Ltd HK$13.07, price HK$4.36, upside +200.0%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · HK · ISIN HK0000311099

CR Thin data Sep 29, 2026

China Resources Pharmaceutical Group Ltd

3320 · HK

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

✓Fair value HK$13.07 · Strongly undervalued (+200.0%)

!Quality 53/100

✓Healthy Growth (revenue 5y +8.4 %/yr)

!Thin margins · 1.5% net margin (TTM)

✓Low debt · generates free cash flow

✓4.8% dividend yield · Well covered

✓Ranks above peers (11/15)

!Narrow moat 28/100

!Evidence only low, so the estimate is less certain

!Weak on future: 10 out of 100

26 models, one by oneBear HK$9.08 to bull HK$16.81 Growth analysisrevenue history, year by year Quality 53/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch China Resources Pharmaceutical Group Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.

How to read this chart

60‑month range HK$2.65 – HK$6.87 · fair‑value band HK$9.08 – HK$16.81 · the HK$4.36 price screens below the HK$13.07 fair value. Dashed = 300-day average. As of Sep 29, 2026.

Follow China Resources Pharmaceutical Group in your weekly email

Every Wednesday you see whether China Resources Pharmaceutical Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular, metabolism, intravenous infusion, and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operating retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, Kun Zhong Yao, and Tasly to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited operates as a subsidiary of CRH (Pharmaceutical) Limited.

Stock analysis

China Resources Pharmaceutical Group Ltd (3320) currently trades at HK$4.36, while our model-based Fair Value estimate is HK$13.07, implying the stock looks roughly 66.7% undervalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of HK$23.41 per share, and 24 of the 26 models we run sit above the HK$4.36 price.

Bear case: the Earnings-Based group reads lowest at HK$6.15, and 2 of the 26 models stay below the price. Evidence for this calculation is low.

Scenario range: HK$9.08 (bear) to HK$16.81 (bull), the price of HK$4.36 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

China Resources Pharmaceutical Group Ltd reported revenue of 300B CNY in FY2025 versus 237B CNY in FY2021, a compound +6.1%/yr. Reported net income was 4.5B CNY in FY2025, compounding +10.0%/yr from FY2021.

Key figures

Market cap HK$27.4B (≈ $3.5B) · P/E ratio 5.6 · P/S ratio 0.08 · Dividend yield 4.8% · Net margin 1.5% · Return on equity 8.3% · Return on assets (EBIT) 4.3% · Operating margin 5.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 29% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 200%, 3320 screens cheaper than that median.

Fair Value models

Bear HK$9.08 Fair Value HK$13.07 Bull HK$16.81

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF HK$19.58 HK$30.06 HK$45.71 78

Growth DCF HK$19.78 HK$28.88 HK$41.56 77

Residual Income HK$8.75 HK$9.21 HK$10.32 76

All 26 models by family

DCF Models

FCF DCF HK$19.58 HK$30.06 HK$45.71 78

Owner Earnings HK$12.18 HK$18.53 HK$28.02 75

5Y Revenue Exit HK$13.94 HK$20.58 HK$28.94 72

5Y EBITDA Exit HK$16.70 HK$25.83 HK$36.44 74

5Y P/E Exit HK$15.43 HK$23.41 HK$31.78 70

10Y Revenue Exit HK$15.54 HK$22.08 HK$30.70 66

10Y EBITDA Exit HK$17.59 HK$25.66 HK$36.38 68

10Y P/E Exit HK$16.79 HK$24.01 HK$32.85 63

Earnings-Based

Graham-Dodd HK$5.70 HK$19.00 HK$25.43 64

Lynch FV HK$4.31 HK$6.15 HK$8.00 61

PEG = 1.0 HK$4.31 HK$6.15 HK$8.00 57

EPV HK$9.45 HK$10.82 HK$12.00 73

Dividend Discount

Gordon GGM HK$0.6300 HK$1.26 HK$1.90 67

DDM Multi-Stage HK$0.6300 HK$1.06 HK$1.33 67

Multiples

P/E Multiple HK$13.83 HK$18.44 HK$23.05 63

P/S Multiple HK$10.69 HK$14.25 HK$17.81 57

P/B Multiple HK$10.69 HK$14.25 HK$17.81 55

EV/EBIT HK$15.46 HK$20.36 HK$25.26 65

EV/EBITDA HK$16.82 HK$22.17 HK$27.52 67

EV/Revenue HK$11.26 HK$15.75 HK$20.24 53

Asset-Based

NCAV (Graham) HK$5.33 HK$7.14 HK$10.66 53

Growth DCF

Growth DCF HK$19.78 HK$28.88 HK$41.56 77

Rev-Margin DCF HK$13.94 HK$20.73 HK$28.75 72

Economic Profit

Residual Income HK$8.75 HK$9.21 HK$10.32 76

ROIC Compounder HK$9.45 HK$10.92 HK$13.44 71

Growth Earnings

Growth-Adj P/E HK$11.65 HK$16.65 HK$21.64 67

Open the full fair value analysis →

Notify me when 3320 reaches fair value

Put 3320 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 53/100

Of which business quality 52 · Market factors (momentum, volatility) 47

Profitability 36

Margins and returns on capital today

Quality Growth 46

Are margins and returns improving?

Cashflow 63

Earnings quality: real cash, not paper profit

Fin. Strength 30

Balance sheet, leverage, solvency risk

Investment 76

Disciplined investing over empire-building

Low Volatility 86

Calm price path (market factor)

Momentum 37

Price trend over the last 3–12 months (market factor)

52W Momentum 18

Distance to the 52-week high (market factor)

Net Issuance 82

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 72/100

Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Revenue growth 1 year

+9.4%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+5.7%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+8.4%

Start year 2020 (pandemic). Over 10 years: +7.4% a year

Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+8.2%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.

+12.7%

Earnings growth per share plus dividend.

Earnings per share, growth per year+7.9%

Dividend (yield on the price)4.8%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.7.9% vs 2.2%, picking up

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 5%

Start year 2020 (pandemic)

Watch 3320, get fair value alerts →

Compare China Resources Pharmaceutical Group Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 625 stocks

Beats the industry median on 11/15 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 53 · Above median

Fair Value upside +200.0% · Top 25%

Profitability

Return on equity (TTM) 8.3% · Above median

Return on assets 5.9% · Above median

Net margin (TTM) 3.4% · Below median

Operating margin (TTM) 5.1% · Below median

Growth and dividend

Revenue growth 2.0% · Below median

Dividend yield (TTM) 4.8% · Top 25%

Balance sheet

Debt / equity 0.37× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 5.6× · Cheapest 25%

P/B 0.41× · Cheapest 25%

P/S (TTM) 0.19× · Cheapest 25%

P/FCF 1.2× · Cheapest 25%

EV/EBITDA 2.0× · Cheapest 25%

PEG 0.98× · Cheaper than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)100 · sector 17

FUTURE (revenue growth)10 · sector 17

PAST (return on equity)33 · sector 26

HEALTH (low debt)81 · sector 96

DIVIDEND (yield)96 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Merck KGaA MRK	€135.00	€108.94	−19%
Takeda Pharmaceutical Company TAK	$18.86	$11.40	−40%
Teva Pharmaceutical Industries Limited TEVA	$39.19	$20.88	−47%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,852	₹1,979	+7%
Galderma Group GALD	CHF 163.00	CHF 110.32	−32%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥44.86	¥49.35	+10%
Haleon plc HLN	$9.26	$8.49	−8%
Sandoz Group SDZ	CHF 71.16	CHF 40.32	−43%
Zoetis Inc ZTS	$71.05	$110.50	+56%
Divi's Laboratories Limited DIVISLAB	₹9,620	₹1,871	−81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

China Resources Pharmaceutical Group Ltd · Fair Value
HK$13.07 +67%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/3320" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">China Resources Pharmaceutical Group Ltd · Fair Value</span><br><b style="font-size:20px">HK$13.07</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+67%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "China Resources Pharmaceutical Group Ltd Fair Value". https://www.fairvalue-calculator.com/stock/3320

Frequently asked questions

Is China Resources Pharmaceutical Group Ltd (3320) overvalued or undervalued?

As of Sep 29, 2026, our model estimates a fair value of HK$13.07 versus a price of HK$4.36, about +200% upside (undervalued).

What is the fair value of 3320?

Our model-based fair value for China Resources Pharmaceutical Group Ltd is HK$13.07 (as of Sep 29, 2026), built from audited fundamentals. The current price: HK$4.36.

What is the quality score of 3320?

China Resources Pharmaceutical Group Ltd has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for China Resources Pharmaceutical Group Ltd (3320)?

Our model-based price target is the fair value of HK$13.07 (as of Sep 29, 2026) from 26 valuation models. Cautious scenario HK$9.08, optimistic scenario HK$16.81. It is a calculation from audited fundamentals, not an analyst target.

What is the China Resources Pharmaceutical Group Ltd stock forecast for 2026?

Our models put fair value at HK$13.07, about +200% upside versus a price of HK$4.36 (undervalued). Cautious scenario HK$9.08, optimistic scenario HK$16.81. The calculation is refreshed regularly with new filings.

What is the revenue of China Resources Pharmaceutical Group Ltd (3320)?

China Resources Pharmaceutical Group Ltd reported trailing-twelve-month revenue of about 272B CNY (latest available figure, as of Sep 29, 2026).

Does China Resources Pharmaceutical Group Ltd pay a dividend?

China Resources Pharmaceutical Group Ltd currently shows a dividend yield of about 4.80% relative to its recent price (as of Sep 29, 2026).

What is the intrinsic value of China Resources Pharmaceutical Group Ltd (3320)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For China Resources Pharmaceutical Group Ltd it is HK$13.07 per share (as of Sep 29, 2026), against a price of HK$4.36. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).

Is China Resources Pharmaceutical Group Ltd stock overvalued or undervalued in 2026?

As of Sep 29, 2026, 3320 trades below its calculated fair value: price HK$4.36, fair value HK$13.07, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 3320?

No. The price is what the market pays today (HK$4.36); the fair value is what the company's own numbers justify (HK$13.07). For China Resources Pharmaceutical Group Ltd the two are HK$8.71 per share apart. That gap is exactly why we show both numbers side by side.

How much is China Resources Pharmaceutical Group Ltd worth?

The market values China Resources Pharmaceutical Group Ltd at about HK$27.4B (market capitalisation, as of Sep 29, 2026). Per share that is HK$4.36; our models calculate a fair value of HK$13.07 per share.

What do the bullish and bearish scenarios say about 3320?

Our models span a range for China Resources Pharmaceutical Group Ltd: cautious scenario HK$9.08, base HK$13.07, optimistic HK$16.81 per share (as of Sep 29, 2026, price HK$4.36). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 3320?

China Resources Pharmaceutical Group Ltd trades at a price-to-earnings ratio of 5.6 (as of Sep 29, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$13.07 is built from several models across several years. Other multiples: PEG 1.0, P/B 0.4, P/S 0.2, EV/EBITDA 2.0.

What is the PEG ratio of 3320?

The PEG ratio of China Resources Pharmaceutical Group Ltd is 0.98 (P/E divided by earnings growth, as of Sep 29, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.

How solid is the balance sheet of China Resources Pharmaceutical Group Ltd (3320)?

Balance-sheet figures for China Resources Pharmaceutical Group Ltd (as of Sep 29, 2026): return on equity 8.3%, debt of 0.37 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.

How far is 3320 from its 52-week high?

China Resources Pharmaceutical Group Ltd trades at HK$4.36, about 29% below its 52-week high of HK$6.17 and 5% above the low of HK$4.14 (as of Sep 28, 2026). Distance from the high says nothing about value: that is what the fair value of HK$13.07 is for.

Which stocks are comparable to China Resources Pharmaceutical Group Ltd?

From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is China Resources Pharmaceutical Group Ltd stock attractive at the current price?

The data as of Sep 29, 2026: price HK$4.36, calculated fair value HK$13.07 (+200%), Quality Score 53/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 3320 calculated?

We run China Resources Pharmaceutical Group Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$13.07, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 15.9 % above its aggregate fair value. China Resources Pharmaceutical Group Ltd currently trades 200 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of China Resources Pharmaceutical Group Ltd (3320)?

The closing price on Sep 28, 2026 was HK$4.36. Our model-based fair value is HK$13.07, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with China Resources Pharmaceutical Group Ltd right now?

The price is below even our cautious bear case (HK$9.08). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (53/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (HK$9.08 to HK$16.81) leaves room in how you read the outcome.

Where does the earnings growth of China Resources Pharmaceutical Group Ltd (3320) come from?

Earnings per share at China Resources Pharmaceutical Group Ltd grew +2.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +5.4 %, EBIT margin −2.5 %, tax rate +0.4 %, residual (interest, one-offs) −1.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of China Resources Pharmaceutical Group Ltd

How large is the market capitalisation of China Resources Pharmaceutical Group Ltd (3320)?

The market capitalisation of China Resources Pharmaceutical Group Ltd is HK$27.4B (≈ $3.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of China Resources Pharmaceutical Group Ltd (3320)?

The price-to-sales ratio of China Resources Pharmaceutical Group Ltd is 0.08 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What is the dividend yield of China Resources Pharmaceutical Group Ltd (3320)?

The dividend yield of China Resources Pharmaceutical Group Ltd is 4.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of China Resources Pharmaceutical Group Ltd (3320)?

The net margin of China Resources Pharmaceutical Group Ltd is 1.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of China Resources Pharmaceutical Group Ltd (3320)?

The return on equity (ROE) of China Resources Pharmaceutical Group Ltd is 8.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of China Resources Pharmaceutical Group Ltd (3320)?

On an EBIT basis the return on assets of China Resources Pharmaceutical Group Ltd is 4.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of China Resources Pharmaceutical Group Ltd (3320)?

The operating margin of China Resources Pharmaceutical Group Ltd is 5.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at China Resources Pharmaceutical Group Ltd (3320)?

Revenue at China Resources Pharmaceutical Group Ltd is growing +2.0% versus a year earlier (3y avg +5.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at China Resources Pharmaceutical Group Ltd (3320)?

Earnings per share at China Resources Pharmaceutical Group Ltd are growing +5.4% versus a year earlier. How much earnings per share grew versus a year earlier.

How much free cash flow does China Resources Pharmaceutical Group Ltd (3320) generate?

The free cash flow of China Resources Pharmaceutical Group Ltd is 18.8B CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net debt does China Resources Pharmaceutical Group Ltd (3320) carry?

The net debt of China Resources Pharmaceutical Group Ltd is 74.3B CNY (fiscal year 2025, ≈ 3.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch China Resources Pharmaceutical Group Ltd in the live analysis

One click puts China Resources Pharmaceutical Group Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.